Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-09-15

Clinical Trial Update: Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the pharmacodynamics of Tafluprost 0.0015% eye drops, comparing preserved and unpreserved formulations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tafluprost (tafluprost)

Snippet

Sponsor: Santen Oy | Conditions: Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2009-09-15